Goserelin
An FDA-approved GnRH agonist decapeptide delivered as a biodegradable implant under the abdominal skin — used for prostate cancer, premenopausal breast cancer, endometriosis, and endometrial thinning, and the only GnRH analogue given as a solid rod rather than an injection.
Goserelin (Zoladex) is a small drug implant placed under the skin of the belly, usually every month or every three months, that switches off the body's production of testosterone or estrogen. It is used for prostate cancer, some breast cancers, and endometriosis. Because it works by overstimulating the system before shutting it down, symptoms can briefly worsen in the first week or two, which doctors plan for.
What is Goserelin?
Goserelin is a synthetic decapeptide GnRH (gonadotropin-releasing hormone) agonist that shuts down sex hormone production by overstimulating the pituitary until it stops responding. It is the same class as leuprolide, triptorelin, buserelin, nafarelin and histrelin, and shares their defining quirk: a one-to-two-week stimulatory 'flare' in LH, FSH and sex steroids before suppression sets in. What makes goserelin distinctive is its delivery. Rather than a depot suspension injected through a conventional needle, goserelin is a solid, biodegradable, one-millimetre cylinder of drug dispersed in a lactide-glycolide copolymer matrix, implanted under the skin of the lower abdomen through a wide-bore applicator and left to erode over 28 days — or, in the 10.8 mg presentation, over 12 weeks. Approved by FDA in December 1989 as Zoladex and now marketed by TerSera, it carries an unusually broad set of indications for a GnRH analogue: advanced and locally confined prostate cancer, advanced breast cancer in pre- and perimenopausal women, endometriosis, and endometrial thinning before ablation.
What Goserelin Is Investigated For
Goserelin's approved indications are all variations on one idea — remove sex steroid drive from a hormone-dependent tissue — and the evidence behind them is deep but uneven across settings. In prostate cancer it is standard androgen deprivation therapy, interchangeable in practice with leuprolide and triptorelin and used both as palliation in advanced disease and, with flutamide, alongside radiotherapy in locally confined disease. In premenopausal breast cancer the strongest single piece of evidence is the 20-year follow-up of the Swedish STO-5 trial, which randomized 924 premenopausal patients to two years of goserelin, tamoxifen, both, or nothing: in the 584 ER-positive patients, two years of goserelin alone cut distant recurrence over two decades (HR 0.49, 95% CI 0.32-0.75), and — the striking finding — the combination was no better than either drug alone, with genomic high-risk tumours benefiting from goserelin and genomic low-risk tumours from tamoxifen. The most-debated use is ovarian protection during chemotherapy, where the evidence genuinely conflicts: the POEMS/S0230 trial reported ovarian failure in 8% of goserelin-treated women versus 22% on chemotherapy alone with more pregnancies and better survival, while the smaller ZORO trial found no difference in return of menses (70.0% vs 56.7%, P = .284). Both are real results; POEMS was larger but hampered by missing primary-endpoint data, ZORO was small and neoadjuvant. Endometriosis and endometrial thinning are approved, narrowly bounded uses — the endometriosis indication is explicitly limited to six months in women aged 18 and over.
History & Discovery
Goserelin began as ICI 118630 at ICI Pharmaceuticals in the United Kingdom — the company that became Zeneca and then AstraZeneca — and it is one of the earliest GnRH analogues to reach the clinic. The first published report of its antitumour activity appeared in the British Journal of Cancer in 1979, when Nicholson and colleagues described ICI 118630 as a new potent luteinizing hormone-releasing hormone agonist with activity against hormone-dependent tumours. That was less than a decade after Andrew Schally's group had isolated and sequenced GnRH itself, and the field was still working out the central paradox of the class: that a GnRH agonist, given continuously rather than in pulses, suppresses the axis it ought to stimulate. The clinical work moved quickly. In August 1983 the Lancet carried two papers from UK groups reporting the treatment of advanced prostatic carcinoma with ICI 118630, establishing both clinical response and the hormonal mechanism behind it. By 1985 the compound was being studied in hormone-dependent breast cancer. The decisive engineering step, though, came in 1984, when Walker and colleagues reported a slow-release depot formulation — the drug dispersed in a biodegradable lactide-glycolide copolymer and implanted subcutaneously as a solid rod. That formulation is what Zoladex still is today, and it remains unique in the GnRH class: every other analogue is given as a liquid depot suspension, a daily injection, a nasal spray, or a surgically placed non-biodegradable implant. Goserelin is the one you place and forget. FDA approved Zoladex on 29 December 1989 under NDA 019726, initially for the palliative treatment of advanced prostate cancer. The 10.8 mg three-month depot followed under NDA 020578 on 11 January 1996. Indications accumulated over the following decade — endometriosis, endometrial thinning before ablation, advanced breast cancer in pre- and perimenopausal women, and locally confined prostate cancer in combination with flutamide and radiotherapy — giving goserelin one of the broadest label footprints of any GnRH analogue. US rights passed from AstraZeneca to TerSera Therapeutics in 2017. Two later research chapters define goserelin's modern profile. The first is the Swedish STO-5 trial, which randomized 924 premenopausal breast cancer patients between 1990 and 1997 and whose 20-year follow-up, published in 2022, produced the unexpected finding that goserelin and tamoxifen each worked but the combination did not improve on either — with the benefit splitting along genomic risk lines. The second is the ovarian protection question, where POEMS/S0230 in 2015 and the ZORO trial in 2011 reached opposite conclusions and left a literature that a 2025 systematic review could summarize but not fully reconcile.
How It Works
The pituitary normally receives GnRH from the hypothalamus in brief pulses, and that pulsing is what keeps it producing LH and FSH. Goserelin floods the receptor continuously instead. For the first week or two the pituitary responds enthusiastically — the 'flare,' when hormone levels briefly rise — and then it stops responding altogether. LH and FSH fall, and with them testosterone in men and estrogen in women, down to the levels of surgical castration or menopause. Hormone-dependent tissues, including many prostate and breast tumours, lose the signal they depend on.
Goserelin acetate is the acetate salt of [D-Ser(But)6, Azgly10]-GnRH — pyro-Glu-His-Trp-Ser-Tyr-D-Ser(But)-Leu-Arg-Pro-Azgly-NH2, molecular weight 1269 Da as the free base. Two modifications of the native decapeptide account for its potency and duration: a bulky tert-butylated D-serine at position 6, which blocks the enzymatic cleavage that gives endogenous GnRH a half-life of minutes, and an azaglycine amide replacing glycine at position 10, which further resists carboxy-terminal degradation. The result is a high-affinity, metabolically stable agonist. Continuous rather than pulsatile occupancy of the pituitary GnRH receptor initially drives supraphysiologic gonadotropin release — the flare, lasting roughly one to two weeks — and then produces receptor downregulation and uncoupling, after which LH and FSH fall and gonadal steroid production collapses to castrate levels in men and postmenopausal levels in women. The implant itself is a second mechanism in its own right: 3.8 mg of goserelin acetate (equivalent to 3.6 mg goserelin) is dispersed through a D,L-lactic and glycolic acid copolymer matrix to a total implant weight of 18.0 mg, formed into a sterile one-millimetre cylinder and placed subcutaneously, where hydrolytic erosion of the polymer releases drug continuously across 28 days. The 10.8 mg presentation uses the same principle over 12 weeks. Suppression is reversible, with gonadal function typically recovering over months after the final implant erodes, though recovery is slower and less certain with prolonged use and in older patients.
Evidence Snapshot
Human Clinical Evidence
Extensive and long-running. FDA-approved since December 1989 for prostate cancer, with subsequent approvals across breast cancer, endometriosis and endometrial thinning, and a 10.8 mg three-month depot approved in January 1996. The evidence base includes randomized trials with follow-up out to 20 years (STO-5), the NEJM ovarian protection trial POEMS/S0230, the contradicting ZORO trial, EBCTCG-level meta-analysis of endocrine therapy in premenopausal women, large real-world registries, and three and a half decades of post-marketing surveillance.
Animal / Preclinical
Comprehensive and historical. Antitumour activity of goserelin (then ICI 118630) was first reported in 1979, and GnRH agonist pharmacology — flare, receptor downregulation, and gonadal suppression — has been characterized across rodent and large-animal models since.
Mechanistic Rationale
Very strong. Continuous GnRH receptor agonism producing pituitary desensitization and consequent gonadal suppression is one of the best-understood endocrine interventions in medicine, and the hormone dependence of the tumours goserelin treats is equally well established.
Research Gaps & Open Questions
What the current literature has not yet settled about Goserelin:
- 01Whether goserelin actually preserves ovarian function during chemotherapy, or whether POEMS captured an effect that ZORO and the neoadjuvant setting could not reproduce. A 2025 systematic review concluded the benefit is real but concentrated in women aged 40 or younger, which is an answer about who rather than whether.
- 02Whether the 20-year STO-5 finding — that goserelin plus tamoxifen is no better than either alone, and may be worse in genomic high-risk disease — holds in modern practice, or is an artefact of a trial designed in 1990 with different chemotherapy and endocrine standards.
- 03Whether goserelin differs clinically from leuprolide or triptorelin at equivalent suppression. Head-to-head randomized data are scarce, and the comparisons that exist are mostly observational or focused on surrogate endpoints.
- 04Whether the 10.8 mg three-month implant achieves suppression equivalent to monthly 3.6 mg dosing in premenopausal women, where estradiol escape has more immediate consequences than testosterone escape does in men — real-world studies are reassuring but not definitive.
- 05The long-term skeletal and cardiometabolic trajectory of women treated with extended ovarian function suppression starting in their thirties or forties, a population that now receives years rather than months of therapy.
- 06Whether the interstitial lung disease signal flagged across antiandrogen agents in FAERS analyses reflects a genuine class effect or reporting artefact, and what absolute risk it corresponds to.
Forms & Administration
Subcutaneous implant only. Goserelin is supplied as a sterile, white-to-cream, biodegradable cylinder approximately one millimetre in diameter, preloaded in a single-use applicator with a wide-bore siliconized needle (16-gauge in the 3.6 mg presentation) and a protective needle sleeve, sealed in a light- and moisture-proof foil pouch with a desiccant capsule. The implant is placed into the fat of the anterior abdominal wall below the navel line using aseptic technique, under the supervision of a physician, and is not removed afterwards — the copolymer matrix erodes as the drug releases. The 3.6 mg implant is given every 28 days; a delay of a few days is permissible but the 28-day schedule should be kept wherever possible. The 10.8 mg implant covers 12 weeks and is used in prostate cancer. Local anaesthetic cream applied in advance is common practice. This is a clinician-administered product and is not self-administered.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
3.6 mg subcutaneous implant, or 10.8 mg subcutaneous implant for the three-month presentation. The implant contains 3.8 mg of goserelin acetate equivalent to 3.6 mg of goserelin, within an 18.0 mg lactide-glycolide copolymer matrix.
Frequency
The 3.6 mg implant is placed every 28 days. The 10.8 mg implant is placed every 12 weeks. A delay of a few days is permissible, but every effort should be made to hold the schedule, since suppression depends on continuous polymer erosion rather than a reservoir.
Timing Considerations
Time of day
No time-of-day preference; scheduling is driven by the 28-day or 12-week interval
Relative to meals
No relationship to food
Relative to exercise
Not tied to exercise timing.
In ovarian protection protocols the first implant is placed at least two weeks before chemotherapy begins. In the locally confined prostate indication, therapy starts eight weeks before radiotherapy.
Cycle Length
Depends entirely on indication. Advanced prostate cancer is intended for long-term administration unless clinically inappropriate. Endometriosis is explicitly limited to six months in women aged 18 and over, because of bone mineral density loss. In the locally confined T2b-T4 prostate indication, goserelin and flutamide are started eight weeks before radiotherapy and continued through it — either a 3.6 mg implant followed 28 days later by a 10.8 mg implant, or four 3.6 mg implants at 28-day intervals, two before and two during radiotherapy. Adjuvant ovarian function suppression in breast cancer is typically given for two to five years depending on regimen and risk.
Protocol Notes
Placement is into the fat of the anterior abdominal wall, below the navel line, with aseptic technique, by a clinician — this is not a self-administered product. The applicator carries a 16-gauge needle in the 3.6 mg presentation because the payload is a solid rod rather than a liquid, and topical anaesthetic applied in advance is common and reasonable. The implant stays in place and biodegrades; it is not retrieved. The flare is the dominant dosing consideration in men. Androgen levels rise for roughly one to two weeks after the first implant before falling to castrate range, and in a man with spinal metastases, impending cord compression or significant urinary obstruction that surge can precipitate a clinical crisis. The standard answer is anti-androgen cover — the US label pairs goserelin with flutamide in the locally confined indication — or, where the flare is genuinely unacceptable, choosing a GnRH antagonist such as degarelix, which produces castrate testosterone within days with no flare at all. Bone health management belongs with any extended course: baseline DXA, calcium and vitamin D, and consideration of a bisphosphonate or denosumab where suppression will run for years. This is a consequence of removing sex steroids, not a peculiarity of goserelin, and it applies equally to men on long-term androgen deprivation and to young women on extended ovarian function suppression. When goserelin is used for ovarian protection during chemotherapy, trials have typically started it at least two weeks before the first chemotherapy cycle and continued it through the last — a scheduling detail that matters, since the protective hypothesis depends on the ovary being quiescent when the cytotoxic drug arrives.
Goserelin is a clinician-administered implant approved for specific oncologic and gynaecologic indications. It is not a wellness product, has no legitimate non-medical use, and its effects on bone, metabolism and fertility are substantial and dose-duration dependent.
Timeline of Effects
Onset
Paradoxical at first. LH, FSH and sex steroids rise for roughly one to two weeks after the first implant — the agonist flare — before falling. Castrate testosterone in men and postmenopausal estradiol in women are typically reached within two to four weeks. Symptomatic effects follow the hormonal ones: hot flashes and loss of libido usually begin as levels fall, while any tumour-related symptom worsening occurs during the flare window.
Peak Effect
Full suppression is maintained for as long as implants are replaced on schedule. In endometriosis, pain relief and lesion reduction develop over the first two to three months of the six-month course. In prostate and breast cancer, PSA or disease response follows suppression over weeks to months. Hot flashes and the metabolic consequences of sex-steroid deprivation persist throughout treatment and often do not attenuate much with time.
After Discontinuation
Recovery is gradual and depends on duration of use and age. After the last implant erodes, pituitary responsiveness returns and gonadal function typically recovers over several months — faster in younger patients and after shorter courses. In the ZORO trial essentially all evaluable women had regular menses two years after chemotherapy regardless of whether they received goserelin, which illustrates both that recovery is usual and that it can take a long time. Bone mineral density lost during treatment recovers incompletely, which is the basis for the six-month limit on the endometriosis indication. In older men after years of androgen deprivation, testosterone recovery may be partial or may not occur at all.
Monitoring & Measurement
Bloodwork & Labs
- •Testosterone in men — confirms castrate suppression (conventionally below 50 ng/dL, with some guidelines using below 20 ng/dL)
- •PSA in prostate cancer, as the primary disease response marker
- •Estradiol and FSH in premenopausal women, to confirm that ovarian suppression has actually been achieved — particularly important before adding an aromatase inhibitor
- •Fasting glucose and HbA1c, given the insulin resistance and new-onset diabetes signal with GnRH agonist therapy
- •Lipid panel
- •Calcium, 25-hydroxyvitamin D and bone turnover markers where extended therapy is planned
Functional & Performance Tests
- •DXA bone mineral density at baseline and periodically during extended therapy — the single most important monitoring test for long courses
- •ECG where QT prolongation risk factors or concomitant QT-prolonging drugs are present
- •Imaging appropriate to the underlying disease (bone scan, CT, MRI) on an oncology schedule rather than a drug schedule
When to Test
Baseline testosterone or estradiol, metabolic panel, lipids and DXA before starting extended therapy. Testosterone and PSA at roughly 3 and 6 months and then at intervals in prostate cancer. Estradiol and FSH to confirm suppression in premenopausal women before and during aromatase inhibitor combination. DXA at baseline and every one to two years on prolonged therapy. Metabolic markers annually.
Interpretation & Notes
The two things worth confirming rather than assuming are suppression and bone. Breakthrough escape from suppression is uncommon but documented — case reports of ovarian ablation failure on goserelin exist — and it matters most in premenopausal women on an aromatase inhibitor, where an unsuppressed ovary turns the combination from effective therapy into a potential stimulus. Checking estradiol and FSH rather than relying on amenorrhoea is the practical safeguard, since chemotherapy-induced amenorrhoea can mimic suppression without providing it. On bone, a baseline DXA before a multi-year course is worth far more than a DXA ordered after a fracture; calcium and vitamin D are inexpensive and standard, and the decision about a bisphosphonate or denosumab depends on baseline density and expected treatment duration. All of this monitoring belongs to the oncology or gynaecology team managing the underlying disease, not to the patient.
Common Questions
How is goserelin given, and why is the needle so big?
Goserelin is not a liquid injection. It is a solid rod about one millimetre across — 18 mg of material, of which 3.6 mg is goserelin dispersed in a lactide-glycolide copolymer that slowly erodes — and placing a solid implant requires a wide-bore applicator, a 16-gauge needle in the standard presentation. It goes into the fat of the anterior abdominal wall below the navel line. The implant is not removed; the copolymer biodegrades while releasing drug continuously over 28 days (or 12 weeks for the 10.8 mg version). Many patients find the applicator intimidating on first sight, and local anaesthetic cream is commonly used; the trade-off is that one placement covers a month or a quarter with nothing to remember in between.
What is the goserelin flare and why does it matter?
Goserelin is an agonist, so the first dose stimulates the pituitary before it desensitizes it. LH, FSH and sex steroids rise for roughly one to two weeks before falling to castrate or postmenopausal levels. In most patients this is simply a transient worsening of symptoms. In a man with impending spinal cord compression from spinal metastases, symptomatic high-burden bone disease, or ureteral obstruction, that surge is clinically dangerous — which is why the prostate label pairs goserelin with flutamide in the locally confined indication and why oncologists cover the flare with an anti-androgen for two to four weeks, or choose a GnRH antagonist such as degarelix that has no flare at all.
Does goserelin actually protect the ovaries during chemotherapy?
The honest answer is that the two best randomized trials disagree. POEMS/S0230, published in the New England Journal of Medicine in 2015, randomized 257 premenopausal women with hormone-receptor-negative breast cancer and found ovarian failure at two years in 8% of the goserelin group versus 22% on chemotherapy alone, with more pregnancies (21% vs 11%) and better disease-free and overall survival — but with enough missing primary-endpoint data that the authors themselves flagged it as weakening interpretation. The ZORO trial, in 60 women with hormone-insensitive disease receiving neoadjuvant chemotherapy, found no significant difference in return of normal menses at six months (70.0% vs 56.7%, P = .284), and nearly all evaluable patients in both arms had regular periods by two years. A 2025 systematic review of 29 studies concluded that the benefit is real but concentrated in women aged 40 or younger. What is not in dispute is that goserelin is not a substitute for embryo or oocyte cryopreservation, which remains the only established fertility preservation strategy.
Should goserelin be combined with tamoxifen in premenopausal breast cancer?
Not automatically, and the 20-year STO-5 data are a genuine caution. In 584 ER-positive premenopausal patients randomized to two years of goserelin, tamoxifen, both, or neither, each single agent reduced 20-year distant recurrence substantially — goserelin HR 0.49, tamoxifen HR 0.57 — but the combination (HR 0.63) was no better than either alone, and the goserelin-by-tamoxifen interaction was statistically significant. Stratified by a 70-gene signature, genomic low-risk tumours benefited from tamoxifen and genomic high-risk tumours from goserelin, and adding tamoxifen to goserelin in the genomic high-risk group was associated with increased risk (HR 3.36, 95% CI 1.39-8.07). This is a secondary analysis of a trial that began in 1990, with modern chemotherapy and endocrine practice having moved on, so it does not overturn current guidelines — but it argues against assuming that stacking endocrine agents is always additive.
Is goserelin banned in sport?
Yes, for men. WADA's S2.2.1 category, 'Testosterone-stimulating peptides in males,' covers GnRH (gonadorelin) and its agonist analogues and names goserelin explicitly alongside buserelin, deslorelin, histrelin, leuprorelin, nafarelin and triptorelin. The prohibition is at all times, in and out of competition, and S2 substances are non-Specified. The entry applies in males only, reflecting the rationale that an agonist can be used to manipulate the testosterone axis. GnRH antagonists such as cetrorelix, ganirelix and degarelix are not named and are not prohibited. A man with a genuine medical indication for goserelin needs a Therapeutic Use Exemption.
Who Goserelin Is NOT For
- •Known hypersensitivity to GnRH, to GnRH agonist analogues, or to any component of the implant — anaphylactic reactions to goserelin have been reported in the medical literature.
- •Pregnancy, except when goserelin is being used for the palliative treatment of advanced breast cancer. Goserelin can cause fetal harm and carries an increased risk of pregnancy loss through its expected hormonal effects.
- •Men with impending spinal cord compression, symptomatic high-burden spinal metastases, or significant ureteral obstruction should not receive goserelin without anti-androgen flare cover, or should be considered for a GnRH antagonist instead.
- •Women with undiagnosed abnormal vaginal bleeding, which must be evaluated before sex-steroid suppression is started.
- •Caution rather than absolute contraindication in patients with established osteoporosis or significant risk factors for fracture, in whom the bone consequences of prolonged sex-steroid suppression may outweigh the benefit — and a hard limit of six months applies to the endometriosis indication for this reason.
- •Caution in patients with significant metabolic disease, pre-existing QT prolongation, or a history of depression, all of which can be worsened by profound sex-steroid deprivation.
Drug & Supplement Interactions
Goserelin has no major cytochrome P450-mediated interactions — it is a peptide, cleared by peptidase hydrolysis rather than hepatic oxidation — so the interactions that matter are pharmacodynamic. The most important is deliberate: anti-androgens such as flutamide or bicalutamide are co-prescribed in men specifically to blunt the testosterone flare during the first weeks of therapy, and flutamide combination is written into the locally confined prostate cancer indication. In premenopausal breast cancer, goserelin is routinely combined with tamoxifen or with an aromatase inhibitor, and the aromatase inhibitor combination is only valid while ovarian suppression is confirmed, since an aromatase inhibitor alone in a woman with functioning ovaries can paradoxically increase estrogen through loss of negative feedback. The STO-5 20-year data complicate the tamoxifen pairing by suggesting the combination may not add to either drug alone and may be harmful in genomic high-risk disease — a signal from a trial begun in 1990 that does not overturn current practice but is worth knowing. Drugs that prolong the QT interval warrant attention given the class effect of androgen deprivation on cardiac repolarization. Bone-modifying agents — bisphosphonates and denosumab — are a standard companion rather than an interaction. Estrogen or testosterone replacement would directly oppose the therapeutic intent, though low-dose add-back therapy is used deliberately in some endometriosis protocols to limit bone loss.
Safety Profile
Common Side Effects
Cautions
- • Bone mineral density loss with extended use — the reason the endometriosis indication is limited to six months and the reason bone health is managed proactively in long-term androgen deprivation
- • Contraindicated in pregnancy except when used for palliative treatment of advanced breast cancer, and goserelin can cause fetal harm
- • Anaphylactic reactions have been reported; goserelin is contraindicated in known hypersensitivity to GnRH, to GnRH agonist analogues, or to any implant component
- • Initial flare can worsen symptoms in men with spinal metastases, urinary obstruction or impending cord compression, and anti-androgen cover is standard in these situations
- • Metabolic consequences of profound sex-steroid suppression — insulin resistance, dyslipidaemia, weight gain, loss of lean mass
- • QT prolongation is a recognized class effect of androgen deprivation therapy
- • A 2026 FAERS pharmacovigilance analysis of antiandrogen agents identified goserelin among seven drugs with a positive disproportionality signal for interstitial lung disease — a rare event, but worth considering in a patient who develops new persistent cough or breathlessness on therapy
- • Hyperglycaemia and new-onset diabetes have been reported with GnRH agonist therapy
What We Don't Know
Goserelin has been in clinical use since 1989 and its acute pharmacology, oncologic efficacy and toxicity profile are thoroughly characterized. The genuine open questions are comparative and contextual rather than basic: whether goserelin differs in any meaningful way from leuprolide or triptorelin at equivalent suppression (head-to-head data are sparse and mostly observational), how reliably the 10.8 mg three-month depot matches the 3.6 mg monthly implant in premenopausal women, whether ovarian protection during chemotherapy is a real effect or an artefact of trial design, and the long-term skeletal and cardiometabolic trajectory of women treated with extended ovarian function suppression at a young age.
Legal Status
United States
FDA-approved prescription implant (Zoladex, NDA 019726 for the 3.6 mg implant approved 29 December 1989, and NDA 020578 for the 10.8 mg implant approved 11 January 1996; currently marketed by TerSera Therapeutics). Approved for locally confined stage T2b-T4 prostate carcinoma in combination with flutamide, palliative treatment of advanced prostate carcinoma, management of endometriosis, endometrial thinning before ablation for dysfunctional uterine bleeding, and palliative treatment of advanced breast cancer in pre- and perimenopausal women. Not a controlled substance. Administered by a clinician; there is no consumer or wellness channel.
International
Approved and widely used across Europe, the United Kingdom, Canada, Japan, Australia, China and much of Asia and Latin America under the Zoladex name, with indications broadly similar to the US label and some regional variation — adjuvant use in premenopausal breast cancer and use in adenomyosis and uterine fibroids are more prominent in some markets. Biosimilar and alternative long-acting goserelin products have been developed in China, including a formulation compared against the originator in a phase 3 non-inferiority trial.
Sports & Competition
Prohibited for male athletes at all times, in and out of competition, under WADA Prohibited List class S2.2.1, 'Testosterone-stimulating peptides in males,' which covers GnRH (gonadorelin) and its agonist analogues and names goserelin explicitly alongside buserelin, deslorelin, histrelin, leuprorelin, nafarelin and triptorelin. The wording is the same in the 2026 and 2027 Lists, and all S2 substances are non-Specified. The entry applies in males only. GnRH antagonists — cetrorelix, ganirelix and degarelix — are not named and are not prohibited. A man with a genuine medical indication requires a Therapeutic Use Exemption, which in an oncology context is ordinarily straightforward to document.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Goserelin is an injection like leuprolide.
Reality
It is a solid implant, not a liquid depot. A one-millimetre rod of drug in a biodegradable copolymer is placed under the abdominal skin through a wide-bore applicator and left to erode. The distinction explains the 16-gauge needle, the common use of local anaesthetic cream, and the fact that nothing has to be mixed or injected — but also that the implant cannot be retrieved once placed if a patient reacts badly.
Myth
Goserelin starts suppressing hormones immediately.
Reality
The opposite happens first. As a GnRH agonist, goserelin drives a one-to-two-week rise in LH, FSH and sex steroids before the pituitary desensitizes and levels fall. In men with symptomatic bone metastases or urinary obstruction that flare is a recognized clinical hazard, which is why anti-androgen cover is standard and why a flare-free antagonist such as degarelix is preferred in high-risk situations.
Myth
Goserelin during chemotherapy preserves fertility.
Reality
It may reduce the rate of chemotherapy-induced ovarian failure — the POEMS trial reported 8% versus 22% at two years with more pregnancies — but the ZORO trial found no significant difference in return of menses, and goserelin is not a fertility preservation strategy in the way embryo or oocyte cryopreservation is. Guidelines treat it as a possible adjunct, not a substitute, and the benefit appears concentrated in women aged 40 or under.
Myth
More endocrine therapy is better, so goserelin plus tamoxifen beats either alone.
Reality
The 20-year STO-5 follow-up found the combination (HR 0.63) no better than goserelin alone (HR 0.49) or tamoxifen alone (HR 0.57), with a statistically significant interaction between the two drugs, and an increased risk when tamoxifen was added to goserelin in genomic high-risk tumours. This is one trial, started in 1990, and does not by itself change practice — but it is a direct empirical argument against assuming endocrine agents stack additively.
Myth
Bone loss on goserelin is minor and fully reversible.
Reality
It is neither minor nor fully reversible, which is why the endometriosis indication carries a hard six-month limit and why bone-modifying agents are standard in long-term androgen deprivation. Recovery after stopping is partial. This is the single most predictable long-term harm of the drug class and the main reason duration is capped wherever the indication allows it.
Published Research
33 studiesInterstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system
Sex and age disparities in goserelin safety: a global pharmacovigilance study
Real-world effectiveness of goserelin 10.8-mg compared to goserelin 3.6-mg in premenopausal and perimenopausal Chinese patients with hormone receptor positive breast cancer
Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study
Efficacy of goserelin in ovarian function suppression and preservation for pre- and perimenopausal breast cancer patients: a systematic review
A 2025 systematic review of 29 prospective studies covering both ovarian function suppression and ovarian function preservation. It concludes that preservation benefits are concentrated in women aged 40 or younger, with higher rates of menstrual recovery, shorter time to recovery, and higher pregnancy rates versus chemotherapy alone. Note that several authors were employees of the product's marketer at the time of the review.
Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer
Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority study
Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer
Clinical efficacy and safety of trimonthly administration of goserelin acetate 10.8 mg in premenopausal Chinese females with symptomatic adenomyosis: a prospective study
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial
Twenty-year follow-up of the Swedish STO-5 trial in 924 premenopausal patients. In 584 ER-positive patients, two years of goserelin alone reduced distant recurrence over two decades (HR 0.49, 95% CI 0.32-0.75), tamoxifen alone HR 0.57, and the combination HR 0.63 — no better than either single agent, with a significant goserelin-tamoxifen interaction. Genomic high-risk tumours benefited from goserelin, genomic low-risk from tamoxifen, and adding tamoxifen to goserelin in high-risk disease was associated with increased risk (HR 3.36).
A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone-releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix)
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
The EBCTCG patient-level meta-analysis defining the modern role of ovarian function suppression in premenopausal ER-positive disease — the framework within which goserelin is used adjuvantly today, and the reason OFS plus an aromatase inhibitor is now a standard option rather than an experimental one.
Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China
The effect of goserelin on the quality of life of women having chemotherapy for early breast cancer: results from the OPTION trial
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer
Goserelin toxicities and preferences for ovarian suppression method in pre-menopausal women with breast cancer
Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy
POEMS/S0230 (Moore 2015, NEJM), 257 premenopausal women with hormone-receptor-negative breast cancer randomized to chemotherapy with or without goserelin. Ovarian failure at two years was 8% versus 22% (OR 0.30, 95% CI 0.09-0.97, P = 0.04), with more pregnancies (21% vs 11%) and improved disease-free and overall survival. The authors explicitly caution that missing primary-endpoint data weaken interpretation — this is the positive half of a genuinely split literature.
Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study
Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes
Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study
The ZORO trial (Gerber 2011, JCO), 60 women under 46 with hormone-insensitive breast cancer receiving neoadjuvant chemotherapy with or without goserelin. Return of normal menses at six months was 70.0% versus 56.7% (difference 13.3%, 95% CI -10.85 to 37.45, P = .284) — not significant — and essentially all evaluable patients had regular menses at two years. The negative counterpart to POEMS, and the reason this indication remains contested.
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial
Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women
Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
Goserelin (Zoladex) - its role in early breast cancer in pre- and perimenopausal women
Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer - self-rated physiological effects and symptoms
Clinical pharmacokinetics of goserelin
Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex)
The 1984 study that introduced the depot implant formulation — the innovation that turned a peptide requiring frequent injection into a monthly subcutaneous rod, and the feature that still distinguishes goserelin from every other GnRH analogue in clinical use.
Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms
Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma
Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist
The 1979 Br J Cancer paper by Nicholson and colleagues reporting antitumour activity of the compound then known as ICI 118630 — the first published demonstration of what would become goserelin, and the origin point of the entire Zoladex program.
Quick Facts
- Class
- GnRH Agonist
- Tier
- B
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Oct 2026
- Citations
- 33PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.